NICE recommends darolutamide with androgen deprivation therapy and docetaxel for patients with hormone-sensitive metastatic prostate cancer
18 May 2023
NICE recommends darolutamide with androgen deprivation therapy and docetaxel for patients with hormone-sensitive metastatic prostate cancer